Pharvaris (PHVS) Other Gross PP&E Adjustments (2021 - 2026)
Pharvaris (PHVS) reported Other Gross PP&E Adjustments of -$836078.6 for Q1 2026, down 9.46% on a YoY basis from -$923442.6 in Q1 2025, and up 5.11% quarter-over-quarter from -$881123.9 in Q4 2025.
Pharvaris (PHVS) Other Gross PP&E Adjustments (2021 - 2026) Analysis & Trends
Pharvaris has reported Other Gross PP&E Adjustments for 6 years, with the latest figure at -$836078.6 in Q1 2026.
- For the quarter ending Q1 2026, Other Gross PP&E Adjustments fell 9.46% year-over-year to -$836078.6; the trailing twelve-month figure through Mar 2026 stood at -$836078.6 (down 9.46% YoY), and the FY2025 full-year result was -$855211.7, up 2.91% from the prior year.
- Other Gross PP&E Adjustments for Q1 2026 stood at -$836078.6, up from -$881123.9 in the prior quarter.
- The five-year high for Other Gross PP&E Adjustments was -$122588.8 in Q3 2024, with the low at -$881123.9 in Q4 2025.
- Historically, Other Gross PP&E Adjustments has averaged -$448214.7 across 5 years, with a median of -$363962.1 in 2023.
- Annual changes were most pronounced in 2024 — Other Gross PP&E Adjustments soared 60.36% — and 2025, when it slumped 435.23%.
- Pharvaris' Other Gross PP&E Adjustments stood at -$441731.4 in 2022, then soared by 43.52% to -$249502.9 in 2023, then sank by 248.56% to -$869667.8 in 2024, then decreased by 1.32% to -$881123.9 in 2025, then grew by 5.11% to -$836078.6 in 2026.
- The last three Other Gross PP&E Adjustments figures came in at -$836078.6 (Q1 2026), -$881123.9 (Q4 2025), and -$656136.8 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Gross PP&E Adjustments (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | -60,691.22 |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | -83,048.00 |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | -285.20 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | -892,000.00 |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | -1.69 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | - |
| 10 | Pharvaris | 28.66 Bn | 28.37 Bn | - | -836,078.64 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -836,078.64 |
| Mar 31, 2026 | -836,078.64 |
| Dec 31, 2025 | -881,123.90 |
| Dec 31, 2025 | -881,123.90 |
| Sep 30, 2025 | -656,136.85 |
| Sep 30, 2025 | -656,136.85 |
| Jun 30, 2025 | -700,244.98 |
| Jun 30, 2025 | -700,244.98 |
| Mar 31, 2025 | -763,816.42 |
| Mar 31, 2025 | -763,816.42 |
| Dec 31, 2024 | -869,667.82 |
| Dec 31, 2024 | -869,667.82 |
| Sep 30, 2024 | -122,588.75 |
| Sep 30, 2024 | -122,588.75 |
| Jun 30, 2024 | -144,282.47 |
| Jun 30, 2024 | -144,282.47 |
| Mar 31, 2024 | -199,326.74 |
| Mar 31, 2024 | -199,326.74 |
| Dec 31, 2023 | -249,502.93 |
| Dec 31, 2023 | -249,502.93 |